In “MOM WARNS BIRTH CONTROL KILLED HER DAUGHTER”, ABC 7 WXYZ.COM, DETROIT, MI, reports on the recent funeral of S. Burns. The 25 year old died and was buried on Mother’s Day 2012, following an aneurysm. In the heart breaking video above, her surviving Mother, Natalie Rogers, explains that YAZ “was the only medication she was on” and that she believed she died from taking the #DROSPIRENONE (#DRSP) containing contraceptive.
(Source: yazrecall.com)
Obama birth control compromise distracts from issue of whether the pill is safe, activists say
From THE WASHINGTON POST - NATIONAL - blog POST
After weeks of uproar over a new requirement that religious employers provide free birth control, President Obama said Friday he had found a compromise.
Norgestrel and Ethinyl Estradiol birth control tablets. (Reuters)
Workers at religious institutions, he said, will get free contraceptiondirectly from health insurance companies instead of their employer. Both sides of the debate welcomed the announcement.
So everybody wins, right?
Everybody except the women taking the pill, some activists say. During the past year, they say, there have been a number of troubling developments concerning birth control, and yet the national discussion remains focused on who is doling it out.
Last month, Pfizer recalled one million packets of birth control pills due to pregnancy concerns, because of a manufacturing mix-up. Several weeks before that, an advisory committee to the FDA said labels on the popular Yaz and Yasmin pills didn’t contain the information they should about possibly causing blood clots. Two different studies found those pills put women at a higher risk of blood clots.
Women began self-reporting health problems like blood clots, too, often on “survivor boards” As of last month, approximately 10,000 lawsuits piled up against Bayer by women who have suffered blood clots or by the families of women who have died while taking Yaz or Yasmin.
And yet the pill continues to see an almost universally positive representation in the media, writes Holly Grigg-Spall in Ms. Magazine, as “a quality of life treatment,” and curer of acne, bloating and anxiety.
Elizabeth Kissling, professor of communication and women’s and gender studies at Eastern Washington University and past president of the Society for Menstrual Cycle Research, wrote recently:
I’m surprised there has not been a broader call for more research, or wider public discussions of the risks of this pill. When a drug company is withholding data and 10,000 lawsuits are pending, more than research is needed. I can’t help but wonder why we’re not seeing congressional hearings–akin to the 1970 Nelson Pill Hearings – again, and more of an outcry from both physicians and patients.
Grigg-Spall thinks there is a lack of education because it helps sustain the profits pharmaceuticals companies.
“In this current climate… it is very difficult for women to have an intelligent, critical discussion about their birth control choices and particularly about the relative dominance of hormonal contraceptives,” she wrote in an email to The Post.
Grigg-Spall started a blog called “Sweetening the Pill,” about the dangers of birth control, because she started feeling depressed after switching to a new brand of pill. But these days, she is outraged about all the women she says she has encountered who have faced even worse side effects.
Friday, Obama sought to soothe a different outrage over birth control. “This is not only unacceptable, it is un-American,” Sen. Joe Manchin (D-W.Va.), a Catholic, had said of the requirement that religious employers provide free birth control. “Correct this decision which will erode the conscience rights,” another Catholic senator, Bob Casey of Pennsylvania, had said.
In Friday’s press conference, Obama corrected that decision. It did not escape activists’ notice, however, that he made no mention of the birth control pill’s possible risks.
By | 04:33 PM ET, 02/10/2012
Tags: National, Obama, birth control, the pill
February 8, 2012 - Sixty (60) Days After FDA Advisory Committee Vote on DRSP (DROSPIRENONE) Containing Birth Control Pills.
Prior to #FDA Advisory Committee hearings, held on 12/8/11, regarding #DRSP (#DROSPIRENONE) containing birth control pills, the manufacturer released a newsletter confirming that it had been ‘served’ with 10,400 lawsuits alleging personal injuries or death. This figure was an estimate as of 10/8/11, two months before the FDA Advisory Committee hearings would consider the latest FDA funded study confirming the pills present a significantly higher risk to users of blood clots that is estimated at 75%-77% higher in comparison to other pills. This finding was released by FDA in late October 2011.
The FDA Advisory Committee voted 15-11 that the pills effectiveness in prevention of pregnancy outweighed their safety risks. This narrow vote of confidence meant the pills barely survived a recommendation that they be the subject of a ‘recall’ or ‘market withdrawal’. Recently released transcripts of the FDA Advisory Committee vote arguably reveal confusion on the vote and a missed opportunity to intervene on behalf of a Generation of #DRSP (#DROSPIRENONE) Vicitms, or YAZ VICTIMS. The FDA Advisory Committee also voted, and recommended, an updated warning label to reflect new and emerging scientific evidence that the pills in fact present higher risks of blood clots to users of all ages. Official FDA action the Advisory Committee recommendations remain pending today - February 8, 2012 - 60 (sixty) days after the Advisory Meeting met and held public hearings.
Gabriel F. Zambrano, P.A., is the author of this commentary. Gabriel F. Zambrano, P.A. is actively investigating cases of blood clots- for YAZ VICTIMS - from the use of #DRSP (#DROSPIRENONE) containing birth control pills: #YASMIN, #YAZ, #BEYAZ, #SAFYRAL, #OCELLA and #GIANVI, as well as related generic equivalents. Additional information is available from Gabriel F. Zambrano, P.A., or by contacting this office directly.
(Source: yazrecall.com)
CNN previously explored events leading up to the FDA’s 12.8.11 Advisory Committee and public hearings on the potential health risk posed by #DRSP (#DROSPIRENONE) containing birth control pills: #YASMIN, #YAZ, #BEYAZ, #OCELLA, #GIANVI and other generics.
In a narrow 15-11 vote the experts on the Advisory Committee decided that the pills were sufficiently effective in the prevention of pregnancy to outweigh the confirmed risk of blood clots they presented to users of all ages. Notably, a growing body of scientific evidence has repeatedly found the pills present a higher risk of blood clots. Estimates vary on the significantly higher risk they pose. However, a FDA funded study found that they are 75%-77% higher risk in comparison to other available birth control pills. The same experts voted that this risk was not adequately presented in current warnings associated with the product. This is significant because the warning labels and inserts had already been revised twice in less than a twenty-four (24) month period. As a result, it is anticipated that the confusing and arguably misleading labels will be revised yet again in coming months.
Sadly, #DRSP (#DROSPIRENONE) containing birth control pills have been available for over a decade in the United States. Recent science confirms that added risk were not communicated, and that scientific research is catching up with the #DRSP (#DROSPIRENONE) family of pills that delivered more risk than was communicated.
Gabriel F. Zambrano, P.A., is the author and sponsor of this post. Gabriel F. Zambrano, P.A., is actively representing girls and women that have suffered catastrophic injuries from blood clots associated with the DRSP (DROSPIRENONE) family of contraceptives. Additional information is available at DRSPRecall
BLOOMBERG BUSINESSWEEK
12.5.11
”BAYER WITHELD YASMIN DATA FROM U.S., FORMER FDA HEAD SAYS”
Bloomberg is reporting that Former FDA Commissioner, David Kessler, has stated that the manufacturer of popular #DRSP (#DROSPIRENONE) containing birth control pills, BAYER, failed to include early disclosures of data that indicated the pills were associated with higher blood clot risks. Higher blood clots, or ‘venous thromboembolism’ (VTE), include deep vein thrombosis (DVT) and pulmonary emboli (PE) and can be fatal if undetected or untreated.
Bloomberg quotes the Former FDA Commissioner as stating that “BAYER presented a selective view of the data, and that presentation obscured the potential risks associated with YASMIN”.
Kessler has been hired as an expert in cases brought against BAYER for failure to warn of risks from the popular line of birth control pills. There are over 10,500 lawsuits pending with civil jury trials scheduled to commence in January 2012.
FDA is scheduled to hold hearings on the risk presented by #DRSP (#DROSPIRENONE) birth control pills on 12.8.11.
Only hours before the BLOOMBERG story was published, HEALTH CANADA
(See related post http://www.gfzambrano.tumblr.com/archive)
announced that it had completed a ‘safety review’ of data on the pills and determined they presented a 1.5x-3.0x higher risk of blood clots.
While all birth control pills carry some risk of blood clots, or other side effects, the lawsuits that arose prior to April 2010 all involve women that did not have the benefit of an warning of increased risk. The manufacturers warnings have ‘evolved’ to include, but also question, studies that the manufacturer claims show risk similar to other forms of hormonal birth control. Today’s announcement by HEALTH CANADA appears to call the manufacturers claims into question.
What the FDA will do next is hold open hearings. Thereafter, they will consider the recommendation of expert panels and comments on the data they are considering. However, one has to wonder openly what added benefit birth control pills with any added risk and no proven superiority to other products offer future Generations of Girls & Women. A Generation of Girls & Women have already been exposed to added risk, arguably unnecessarily, and challenged as they come forward to present their claim with prior studies that Former FDA Commissioner Kessler’s testimony calls into question. A #YAZ recall, or #DRSP recall, may be a consideration, however that will do little to compensate girls and women that have already suffered, while the pills prospered as a brand and reached Blockbuster status. Any additional updates on a recall will be posted at YAZRecall.com
Gabriel F. Zambrano, P.A., is the author/sponsor of this blog and commentary.
Gabriel F. Zambrano, P.A., is actively investigating cases of serious personal injuries arising out of the use or #DRSP #DROSPIRENONE containing birth control pills. As YAZ LAWYER @YAZATTORNEY he has been providing free updates and information on the risks and dangers of #DRSP #DROSPIRENONE birth control pills for over 2 (two) years. Gabriel F. Zambrano is a Member of the YAZ MDL 2100 Discovery Committee, Lead Counsel and/or Co-Counsel of several women among 1st 100 YAZ Lawsuits filed in YAZ MDL and State Mass Tort Proceedings, has been selected to conduct depositions(s) of BAYER Corporate Representatives by State Liaison Counsel on behalf of coordinated Mass Tort Proceedings in YAZ MDL 2100, and Admitted Pro Hace Vice in PA YAZ Mass Tort Proceedings as Legal Representative of one of 1st 100 DRSP Lawsuits filed in PA Mass Tort Proceedings. Please contact the author with any requests for additional information or a FREE CASE EVALUATION. Additional information is available at YAZRecall.com
Vermont Journalism Trust reports on 11.21.11 death of April Bapp allegedly linked to #DRSP (#DROSPIRENONE) birth control generic OCELLA. FDA hearings on increased blood clot risks are set for 12.8.11.
Editor’s note: This article, by Tena Starr, was first published in the Barton Chronicle.
On late Saturday afternoon, Nov. 12, when April Bapp of Brownington got a phone message from her daughter Rebecca, who didn’t feel well and was having trouble breathing. She was working that day at Community College of Vermont in Newport, and there was no one else in the building. She didn’t think she could get herself to a doctor, so her parents drove to Newport and brought her to North Country Hospital.
Six hours later Rebecca was dead. She was 21 years old.
“She couldn’t get enough oxygen in her lungs,” Mrs. Bapp said. “Her sugar was high. They weren’t sure what was going on. She was on a breathing machine, sedated, they wanted to do a CT to see what was going on, and she coded.”
The hospital had planned to Medivac her to the Dartmouth Hitchcock Medical Center in Lebanon, N.H., but Rebecca coded again. The third time, doctors couldn’t bring her back, and she died that night.
Baffled, her family asked for an autopsy. The medical examiner’s report said she died of a blood clot in her heart, April Bapp said. “And the secondary cause of death was her oral contraceptive.”
Rebecca had been taking Ocella, a relatively new and controversial type of birth control pill that is the subject of a federal advisory committee hearing this week. The prescription is also known by its popular generic brand name YAZ.
YAZ has been the suspected cause for deaths around the country, according to the Public Citizens Health Research Group.
Dr. Sidney Wolfe, director of the watchdog organization, said, “there have been a number of published studies not connected with the company that have found problems with the product.”
The organization, which Wolfe founded 40 years ago with consumer advocate and former presidential hopeful Ralph Nader, has placed YAZ on its list of “do not use” drugs.
Public Citizen’s Worst Pills, Best Pills website says that GIANVI, YASMIIN, YAZ, and ZARAH are on the “do not use” list because they can cause increased blood levels of potassium and are no more effective than other oral contraceptives in preventing pregnancy.
The federal Food and Drug Administration’s Drug Safety and Risk Management Advisory Committee, of which Dr. Wolfe is a member, will receive a briefing on this week regarding the newest information about third-generation birth control pills, Dr. Wolfe said.
The advisory committee will examine whether the product should even be on the market, he said. New information will be available on the FDA’s website later this week. (Public Citizen sued the FDA some time ago, forcing the agency to post information on its website in a timely fashion.
For her part, April Bapp said YAZ and its relative Ocella were highly marketed products that her daughter and her doctor apparently trusted. “Those ads came across as being great and wondrous,” she said. “This is the brand they’re pushing to young girls.”
April Bapp is shocked by the sudden death of her daughter, and she is hoping that, by talking about it, she can prevent the unnecessary death of another young woman.
“If we can prevent someone else from dying, then it may help us make some sense of Rebecca’s death,” she said in a letter to the Chronicle.
“She worked at the Farm Service Agency, she worked at CCV on Saturdays, she helped out the town clerk,” April Bapp said. “She was working on her bachelor’s degree at Johnson State College. There was so much potential.”
More than 300 people attended Rebecca’s funeral.
“Everybody said how smart she was,” April Bapp said. “Rebecca’s boyfriend, they were all there on short notice for her death. It’s just not what you think is going to happen when your daughter calls and says she doesn’t feel good.”
Although April Bapp was aware that birth control pills carry health risks, her daughter’s death and the autopsy results prompted Mrs. Bapp to question the risk associated with this particular birth control pill.
YAZ, which the FDA approved in 2006, is among a newer line of birth control pills that includes other brand names such as Yasmine and Ocella. The difference between those brands and older birth control pills is that YAZ and its counterparts contain drospirenone, a progestin — basically a hormone — that is not contained in older birth control pills.
Information from the FDA is contradictory. It says that several studies have been conducted, and some indicate a higher risk for blood clots, stroke, and other problems when taking YAZ, and some do not.
“All birth control pills pose a risk of blood clots,” a September FDA website posting on the product says. “Several epidemiological studies have reported that the risk of blood clots for women who use birth control pills containing drospirenone is higher than that for women who use birth control pills containing the progestin levonorgestrel. Other studies have not reported an increase in risk.”
Levonorgestrel is the hormone in an older generation of birth control pills.
Later studies indicate an increased risk, according to the FDA, which commissioned yet another study. The results are being finalized and may be reviewed later this week by the advisory committee. Recent articles in the British Medical Journal reported a two- to three-fold greater risk of blood clots and other serious problems in women who use oral contraceptives containing drospirenone.
YAZ has been the suspected cause for deaths around the country, according to the Public Citizens Health Research Group.
An article posted on the Worst Pills website said that studies funded by the industry found lower risks of blood clots than did studies that were publicly funded. It says that drospirenone is “a close chemical cousin of spironolactone, a diuretic or water pill that causes the body to retain potassium. A 3-milligram dose of drospirenone, the amount in a daily contraceptive pill, is equivalent to 25 milligrams of spironolactone.”
A 2008 “warning” letter to Bayer HealthCare Pharmaceuticals, Inc., the company that manufactures and markets YAZ, is posted on the FDA’s website. Thomas Abrams, director of the Division of Drug Marketing, Advertising, and Communications at the U.S. Department of Health and Human Services wrote that the company was, at the time, engaged in misleading advertising practices.
“The TV ads are misleading because they broaden the drug’s indication, overstate the efficacy of YAZ, and minimize serious risks associated with the use of the drug,” the letter says. “These violations are concerning from a public health perspective because they encourage use of YAZ in circumstances other than those in which the drug has been approved, over-promise the benefits and minimize the risks associated with YAZ.”
The ads indicated that YAZ not only was an effective birth control pill, but also treated severe acne and premenstrual syndrome. Apparently, it does benefit acne problems to some extent, and also helps with premenstrual dysphoric disorder, a serious form of PMS.
The FDA warned that some of the television ads were over the top. One, called “Not Gonna Take It,” started by saying, “We all know that birth control pills are 99 percent effective and can give you shorter, lighter periods. But did you know there’s a pill that could do more?”
“It then displays images of energetic, euphoric, playful women singing ‘We’re not gonna take it’ as they kick, punch and push words describing symptoms such a irritability, moodiness, bloating, and feeling anxious away from the screen…” Abrams writes in his letter to Bayer.
He goes on to say that the product is not approved to treat severe acne or PMS, and the ads do not appropriately explain the risks involved in taking the product.
A New York Times article says that YAZ is the “go-to-selling” birth control pill in the U.S. and owes much of its popularity to a multi-million-dollar ad campaign that promotes it as a quality-of-life treatment that combats acne and severe premenstrual depression, as well as preventing pregnancy. The story goes on to say that the American unit of Bayer rigorously defends the safety of the product and says it has been extensively studied.
A New Jersey Business magazine article tells a story that resembles that of the Bapps’. It says that Michelle Pfleger, a teenager, asked for the birth control pill YAZ when she visited her doctor before going off to college. She’d seen the advertisements on television. The young woman died after a blood clot lodged in her lung while she was on her way to class at Elon University in North Carolina, the article says. Ms. Pfleger was 18.
The article says that more than 900 lawsuits have been filed in Bergen County, New Jersey , and that hundreds of other cases have been lodged in Philadelphia, California and Illinois.
Contacted Tuesday, a spokesman for Bayer did not comment except to say the company does not make Ocella.
No one from Tava, which does, responded to email.
Mrs. Bapp is doing the best she can these days.
“You try to put on a good front when you’re out,” she said. “But it’s devastating.”
Her other daughter has posted the cause of her sister’s death on Facebook in the hope of informing people.
Other contraceptives that contain drospirenone are Angeliq, Beyaz, Gianvi, Safyral, and Zarah.
Consumers may report serious problems with oral contraceptives or other products to the FDA’s MedWatch Adverse Event Reporting program at (800) FDA-1088, or www.accessdata.fda.gov/scripts/medwatch/medwatch-online.tm.
The video above was broadcast on January 21, 2011, by “MARKETPLACE: Canada’s Consumer Watchdog”, and was entitled “Spinning A Pill”. The video feature is over 15 minutes and highlights the stories of several #DRSP #DROSPIRENONE survivors of pulmonary emboli. Sadly, it also includes the story of a family that lost a daughter to injuries from a #DRSP #DROSPIRENONE containing birth control pill while in a medical facility.
What makes the “Spinning A Pill” video particularly interesting is that fact that “MARKETPLACE: Canada’s Consumer Watchdog” shows how celebrities and athletes were used to promote use of #DRSP #DROSPIRENONE containing contraceptives. Basically, a popular actress, and athletes were utilized in a direct to consumer campaign to make these pills ‘top of mind’ choices to girls and women. In fact, the trademarked name “YASMIN”, the predecessor to “YAZ”, was emblazoned on the back of a professional volleyball players bikini bottom, and armband, so that it was prominently displayed. Similarly, a younger demographic was arguably targeted, through the public endorsement of a petite and fashionable actress who lauded how use of the pill put her in some form of ‘control’ over her body.
Granted, the above appear to have been efforts to convert Canadian users, or attract consumers to the #DRSP #DROSPIRENONE family of pills in, or from, Canadian markets. Aggressive marketing in the United States has been the subject of FDA Warning Letters, corrective advertising and payments of $20 Million Dollars to the Attorney Generals of 27 States. Regardless, the very ‘in your face’ marketing of these pills has allowed them to continue growing in popularity despite a growing body of scientific evidence, medical literature and open concern by the Food & Drug Administration (FDA).
As noted in prior posts, there are thousands of lawsuits, with estimates over 10,000, in the United States against the manufacturer of #DRSP #DROSPIRENONE containing birth control pills - BAYER HEALTHCARE PHARMACEUTICALS - alleging serious personal injuries and even death. Just this past week, during October 25, 2011 and October 27, 2011, two studies addressing the increased relative risk of blood clots these pills pose to users were released. Only last month, on September 26, 2011, FDA announced that it had only reached preliminary results of their ongoing evaluation of research and evidence on the risks posed by #DRSP #DROSPIRENONE birth controls pills and that it would convene a joint panel of experts on December 8, 2011, to evaluate this information and conduct public hearings. What does the future hold for #DRSP #DROSPIRENONE containing birth control users? How will the FDA act following these hearings and their own finding that these pills present a 1.74x risk of blood clot? We will see.
Despite the recent studies, repeated FDA action, the need for corrective advertisements, $20 Million in fines, and over 10,000 lawsuits, recently released reports indicate that the use and profit motive for #DRSP #DROSPIRENONE containing pills continues as the “YAZ franchise” reportedly grew 16.5%. Yet the entire “YAZ franchise” only seems to add a layer of additional risk to users, while older pills and generics, with a proven safety record remain on the pharmacy shelf. Why? How? Marketing across age groups ranging from early teens and up.
Prior posts relating to #DRSP #DROSPIRENONE pills, as well as others can be found via this link.
(Source: recallattorneys.com)
ABC’s Good Morning America (#GMA) reports on the dangers of #DRSP #DROSPIRENONE pills and cites #BAYER as stating they are safe and effective when used as directed. Yet, on September 26, 2011, the FDA scheduled public hearings for December 8, 2011, regarding continued concerns of blood clots, as well as emerging body of scientific evidence that #YASMIN #YAS or #DRSP #DROSPIRENONE birth control pills are blood clotting hazard of 1.5x to 3.0x more likely.
Gabriel F. Zambrano, P.A., is the sponsor of this blog and commentary. Gabriel F. Zambrano, P.A., is an advocate of the dangers of #DRSP #DROSPIRENONE pills and posts related news @yazattorney @gfzambrano and @recallattorneys. Gabriel F. Zambrano, P.A. is actively investigating DRSP LAWSUITS, and representing women that suffered personal injuries from DROSPIRENONE containing birth controls pills. Gabriel F. Zambrano, P.A., is a member of the Federal MDL Discovery Committee, Representative Counsel or Co-Lead of several of the 1st 100 YAZ Bellwether Discovery Cases, Admitted Pro Hac Vice in the coordinated Mass Tort Proceedings in PA, that proudly represents survivors of DRSP injuries. Please REPOST.
(Source: yazbitterpills.com)
#Drospirenone lawsuits, #DRSP lawsuits, or #YAZ Lawsuits, involve the popular family of birth control pills, manufactured by #BAYER, and trademarked as #Yasmin #YAZ #BEYAZ or #SAFYRAL. While #BEYAZ & #SAFYRAL were only introduced last year, they also contain the controversial progestin - #DRSP #drospirenone. The FDA is holding a public advisory meeting in December 2011 to discuss the blood clot risks, and their continued ‘concern’ over, risks posed by this progestin.
The images above come from BAYER’s June 2011 Stockholder Newsletter and disclose over 9,300+ served #DRSP #lawsuits or #YAZ Lawsuits or Claims as of July 2011.
Additional information, as well as a link to a FREE #YAZ #LAWSUIT CASE EVALUATION, or #DRSP LAWSUIT CONSULTATION, is available through DRSP Lawsuits and this link.
Gabriel F. Zambrano, P.A., is the author of this blog and commentary, as well as DRSP Lawsuits. Gabriel F. Zambrano is actively representing and screening cases for DRSP survivors and a member of the MDL Discovery Committee; Representative Counsel or Lead Counsel for several of the 1st 100 YAZ Claims filed in the MDL and State Court proceedings, as well as a recognized thought leader in advocating against #DRSP #drospirenone pills.
When it comes to the promotion of the #DRSP #drospirenone family of birth control pills, have you really forgotten about the ‘corrective ads’? #Recall the ads? Above is a link from YouTube to the FDA required corrective ad that followed an FDA Warning Letter. This ad was part of a $20 Million Dollar Settlement with 27 States and the Attorney’s General of those states for violation of a prior settlement agreement regarding #BAYER’s Blockbuster drug - Baycol.
Approximately a year later, MDL (Multi District Litigation) and coordinated mass tort proceedings in PA, CA & NJ were commencing with lawsuits alleging injuries that include:
- Death
- Heart Attacks
- Strokes
- Pulmonary Emboli (PE)
- Deep Vein Thrombosis (DVT)
- Gallbladder Removal and complications from invasive surgery
- Pancreatitis
Between April 2010 and April 2011 there have been two (2) changes to the warning label inserted in the box that comes with this 4th Generation family of birth control pills. Those changes now warn of an increased risk of blood clots but were initially an effort - in my opinion - to spin recently published science in favor of the manufacturer. These changes, and ongoing evaluations of the dangers associated with #DRSP #drospirenone pills, are little consolation to girls and women that wish they had never taken one of these pills. Many, but not all are now litigants in cases described above. Trials are scheduled in early 2013 in front of civil juries to determined what was known by the manufacturer, and whether they failed to adequately disclose already known risks to unsuspecting women. Given that #BAYER developed and promoted #DRSP #drospirenone as a new and unique progestin with multiple ‘benefits’ it is becoming clear that girls and women, were arguably, not fully informed.
I have already commented in prior posts on the 9.26.11 FDA update regarding the conflicts in scientific evidence and scheduled advisory hearings to discuss the now recognized increased risk of taking a #DRSP #drospirenone birth control pill. Whether the risk is 1.5x or 3.0x more likely to create a blood clot is presently debated. However, the avoidable suffering of girls, women and their loved ones is not as 9,500+ lawsuits claiming a litany of ailments continue to mount.
I Gabriel F. Zambrano, P.A., am the author and sponsor of this commentary and blog. I have been actively investigating and representing victims of DRSP drospirenone birth and continue to provide a free case evaluation and screening. Additional, public information, new stories, science and a history of this litigation exists at the following on Facebook: “Yasmin & YAZ Claims/Lawsuits”. I also provide related news and updates via Twitter @yazattorney.
